Dapagliflozin for Cardiovascular Risk
(DAPA-SWEET Trial)
Recruiting in Palo Alto (17 mi)
Overseen byDavid ZI Cherney, MD PhD FRCPC
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Recruiting
Sponsor: University Health Network, Toronto
Prior Safety Data
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?This study aims to elucidate the impact of SGLT2 inhibition on peripheral vascular function, renal function, fluid volume, neurohormonal activation and inflammatory/fibrotic pathways in patients with T2D at high cardiovascular risk and non-T2D patients.
Eligibility Criteria
Inclusion Criteria
Blood pressure < or = 160/100 at screening (sitting)
eGFR ≥30 ml/min/1.73m2
In patients with type 2 diabetes, HbA1c <12.0%
+4 more
Exclusion Criteria
Pre-menopausal women who are nursing, pregnant, or of child-bearing potential and not practicing an acceptable method of birth control
Participation in another trial with an investigational drug within 30 days of informed consent
Type 1 Diabetes
+17 more
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Dapagliflozin Treatment ArmExperimental Treatment1 Intervention
Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
Group II: Placebo ArmPlacebo Group1 Intervention
Placebo Matching Dapagliflozin Tablet for 12 weeks
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Renal Physiology LaboratoryToronto, Canada
Loading ...
Who Is Running the Clinical Trial?
University Health Network, TorontoLead Sponsor
Sunnybrook Health Sciences CentreCollaborator
MOUNT SINAI HOSPITALCollaborator